[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.244.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 371
Citations 0
Comment & Response
April 2017

Statistical Concerns on Vismodegib for Basal Cell Carcinoma Meta-analysis

Author Affiliations
  • 1Melanoma Unit, AC Camargo Cancer Center, Rua Professor Antonio Prudente, São Paulo State, Brazil
JAMA Dermatol. 2017;153(4):337. doi:10.1001/jamadermatol.2016.5689

To the Editor The recent meta-analysis published by Jacobsen and colleagues1 in JAMA Dermatology amalgamated all available evidence pertaining the role of vismodegib for locally advanced and metastatic basal cell carcinoma. Well-conducted meta-analyses can provide more accurate estimates of response and safety and investigate further the reasons for clinical discrepancies across studies.2

×